Revenue and Income - Total revenues for Q1 2025 were $47 million, a 14% year-over-year decrease due to the discontinuation of the staffing business and divestitures [4]. - Total revenues for the three months ended March 31, 2025, were $47,328,701, a decrease of 13.7% compared to $54,808,042 for the same period in 2024 [17]. - Net income attributable to SBC Medical Group increased by 15% year-over-year to $22 million, compared to $19 million in Q1 2024 [6]. - Net income attributable to SBC Medical Group Holdings Incorporated for Q1 2025 was $21,502,446, representing an increase of 14.7% from $18,757,752 in Q1 2024 [17]. EBITDA and Margins - EBITDA for Q1 2025 was $25 million, representing a 3% year-over-year decrease, with an EBITDA margin of 52%, up from 46% in Q1 2024 [4]. - EBITDA for the three months ended March 31, 2025, was $24,830,378, with an EBITDA margin of 52%, compared to an EBITDA of $25,479,362 and a margin of 46% in Q1 2024 [23]. - Operating margin improved from 45% in Q1 2024 to 51% in Q1 2025, showcasing enhanced profitability [3]. Customer Metrics - The total number of customers in the last twelve months ended March 31, 2025, was 6.1 million, reflecting a 14% year-over-year increase [4]. - The repeat customer rate for franchise clinics was 71%, indicating strong customer loyalty [4]. - The number of partner clinics increased to 251 as of March 31, 2025, an increase of 36 clinics from the previous year [4]. Cash and Assets - Cash and cash equivalents as of March 31, 2025, were $132.06 million, an increase from $125.04 million at the end of 2024 [12]. - Cash and cash equivalents at the end of the period increased to $132,055,823, up from $96,181,550 at the end of Q1 2024 [21]. - Total assets increased to $284.61 million as of March 31, 2025, compared to $266.08 million at the end of 2024 [15]. Operating Expenses and Other Income - Operating expenses decreased to $13,531,010 in Q1 2025 from $15,058,490 in Q1 2024, reflecting a reduction of 10.1% [17]. - The company reported a gain on redemption of life insurance policies amounting to $8,746,138 in Q1 2025 [17]. - Interest income increased to $55,333 in Q1 2025, compared to $17,689 in Q1 2024, marking a growth of 212.5% [17]. - The net cash provided by operating activities for Q1 2025 was $1,928,621, down from $3,682,175 in Q1 2024 [21]. - The company experienced a foreign currency translation adjustment resulting in other comprehensive income of $9,808,327 in Q1 2025, compared to a loss of $10,193,852 in Q1 2024 [17]. Share Information - The weighted average shares outstanding for basic and diluted earnings per share increased to 103,276,637 in Q1 2025 from 94,192,433 in Q1 2024 [17]. Strategic Focus - The company is focusing on strategic expansion and optimizing its profitability structure to adapt to changing market dynamics [3].

Financial Performance - Total revenues for the first quarter of 2025 were $47 million, reflecting a 14% year-over-year decrease due to the discontinuation of the staffing business and divestitures[4] - Net income attributable to SBC Medical Group increased by 15% year-over-year to $22 million, compared to $19 million in the same period of 2024[6] - EBITDA for the first quarter of 2025 was $25 million, representing a 3% year-over-year decrease, with an EBITDA margin of 52%, up from 46% in the first quarter of 2024[4] - Total revenues for the three months ended March 31, 2025, were $47,328,701, a decrease of 13.7% compared to $54,808,042 for the same period in 2024[17] - Net income attributable to SBC Medical Group Holdings Incorporated increased to $21,502,446, up 14.7% from $18,757,752 in the prior year[17] - EBITDA for the three months ended March 31, 2025, was $24,830,378, with an EBITDA margin of 52%, compared to an EBITDA of $25,479,362 and a margin of 46% in 2024[23] - Operating expenses decreased to $13,531,010, down 10.1% from $15,058,490 in the previous year[17] - The company reported a gain on redemption of life insurance policies amounting to $8,746,138, which was not present in the prior year[17] - Interest income rose to $55,333, compared to $17,689 in the same period last year, reflecting a significant increase[17] - The company reported a total other income of $7,249,333, significantly higher than $2,741,315 in the same period last year[17] Customer Metrics - The number of partner clinics increased to 251 as of March 31, 2025, an increase of 36 clinics from the previous year[4] - The total number of customers in the last twelve months ended March 31, 2025, was 6.1 million, marking a 14% year-over-year increase[4] - The repeat rate for customers who visited franchisee clinics twice or more was 71%[4] Profitability and Margins - Operating margin improved from 45% in the first quarter of 2024 to 51% in the first quarter of 2025[3] - Return on equity was 41%, representing a year-over-year decrease of 10 percentage points[4] Strategic Focus - SBC Medical is focusing on strategic expansion and optimizing profitability through revised pricing strategies and adapting to market dynamics[3] - The company aims to build a scalable franchise model while accelerating expansion across domestic and international markets[3] Cash and Other Financial Adjustments - Cash and cash equivalents at the end of the period increased to $132,055,823, compared to $96,181,550 at the end of the same period in 2024[21] - The company experienced a foreign currency translation adjustment resulting in other comprehensive income of $9,808,327, compared to a loss of $10,193,852 in 2024[17] - Net cash provided by operating activities was $1,928,621, a decrease from $3,682,175 in the prior year[20]

Financial Results Announcement - Cloudastructure, Inc. announced its financial results for the quarter ended March 31, 2025[5]. - The press release detailing the financial results was issued on May 15, 2025[5]. - No specific financial metrics or performance indicators were disclosed in the provided content[5]. - The document does not include any information on user data, future outlook, or new product developments[5]. Company Classification and Listing - The company is classified as an emerging growth company under the Securities Act[4]. - The trading symbol for Cloudastructure, Inc. is CSAI, listed on the Nasdaq Capital Market[3]. Corporate Information - The principal executive office is located at 228 Hamilton Road, Palo Alto, California[1]. - The report was signed by Greg Smitherman, Chief Financial Officer[13]. - The filing includes an interactive data file with embedded XBRL tags[8]. Financial Standards - The company has not elected to use the extended transition period for new financial accounting standards[4].

Financial Performance - The net loss from operations for the year ended December 31, 2024, was approximately $21.6 million, an increase from approximately $16.8 million in 2023, primarily due to merger-related costs of $3.3 million and restructuring costs of $1.7 million[6]. - The company reported a net loss of $19.8 million for the year ended December 31, 2024, compared to a net loss of $10.0 million in 2023[19]. - Total operating expenses for 2024 were $21.6 million, compared to $16.8 million in 2023, reflecting the impact of merger-related expenses and increased R&D costs[19]. Research and Development - Research and development expenses for 2024 were reported at $7.0 million, compared to approximately $5.5 million in 2023, while general and administrative expenses decreased to approximately $9.7 million from $11.4 million[7]. - The lead candidate, AKTX-101, is a TROP2 PH1 ADC with a novel spliceosome inhibitor payload, showing superior activity and prolonged survival in preclinical models compared to existing ADCs[4]. - The company plans to continue advancing its pipeline by generating additional validating data on its PH1 payload while exploring new novel payloads PH5 and PH6[10]. Merger and Strategic Focus - Following the merger with Peak Bio, Inc. in November 2024, the company is focusing on the discovery and development of novel anti-cancer payloads that differ from currently approved ADC therapies[3]. - The company aims to secure development partners for its legacy pipeline assets to provide non-dilutive capital[5]. Financial Position - As of December 31, 2024, the company had cash of approximately $2.6 million, and with the net proceeds from a private placement of $6.6 million announced in March 2025, it is expected to fund operations into September 2025[8]. - The total assets as of December 31, 2024, were $50.6 million, significantly up from $4.4 million in 2023, primarily due to the merger[17].

Financial Performance - As of March 31, 2025, the company reported a net income of $4,017,775, which included $3,977,942 of interest income from the Trust Account[113]. - The company had a cash balance of $1 and a working capital deficit of $10,259,448 as of March 31, 2025[114]. - The company reported no revenues to date, with all activities focused on preparing for the Public Offering and searching for a target business[112]. - The company incurred $30,000 in administrative fees for both the three months ended March 31, 2025, and 2024, for office and administrative support[121]. - The company has incurred general and administrative expenses of $2,036,401, offset by waived legal fees of $2,076,234, for the three months ended March 31, 2025[113]. Public Offering and Financing - The company completed its Public Offering on November 13, 2023, raising gross proceeds of $345.0 million from the sale of 34,500,000 units at $10.00 per unit, incurring transaction costs of approximately $20.4 million[106]. - The underwriters received an underwriting discount of $6,900,000 and deferred underwriting commissions of approximately $12,075,000, contingent upon the completion of a business combination[119][120]. - The company has placed approximately $345.0 million in a Trust Account, invested in U.S. government securities, until the completion of its initial business combination[108]. - The company issued a Working Capital Note for $1,500,000 to Warrant Holdings Sponsor, which is repayable upon the consummation of an initial business combination[122]. Business Viability and Compliance - The company has until November 13, 2025, to complete a business combination or cease operations, raising substantial doubt about its ability to continue as a going concern if a business combination is not consummated[117]. - The Company complies with ASC 340-10-S99 and SEC Staff Accounting Bulletin Topic 5A regarding offering costs, which primarily consist of professional and registration fees related to the Public Offering[124]. - Offering costs allocated to Class A ordinary shares were charged to temporary equity, while those allocated to Warrants were charged to shareholders' equity[124]. - The Company qualifies as an "emerging growth company" under the JOBS Act, allowing it to delay the adoption of new or revised accounting standards[127]. - As an "emerging growth company," the Company is exempt from certain reporting requirements for a period of five years following the Public Offering[128]. - The Company did not have any off-balance sheet arrangements as of the date of the Quarterly Report on Form 10-Q[126]. - The Company is classified as a smaller reporting company and is not required to provide certain market risk disclosures[130].

Financial Performance - As of March 31, 2025, the company reported a net income of $4,017,775, which included $3,977,942 of interest on the Trust Account[113]. - The company had a cash balance of $1 and a working capital deficit of $10,259,448 as of March 31, 2025[114]. - The company generated non-operating income from interest on marketable securities but has not engaged in any operations or generated revenues to date[112]. Public Offering - The company completed its Public Offering on November 13, 2023, raising gross proceeds of $345.0 million from the sale of 34,500,000 units at $10.00 per unit, incurring transaction costs of approximately $20.4 million[106]. - The underwriters received an underwriting discount of $6,900,000 and deferred underwriting commissions of approximately $12,075,000, contingent upon the completion of a business combination[119][120]. - Offering costs allocated to Class A ordinary shares were charged to temporary equity, while those allocated to Warrants were charged to shareholders' equity[124]. Business Viability - The company has until November 13, 2025, to complete a business combination or cease operations, raising substantial doubt about its ability to continue as a going concern if a business combination is not consummated[117]. Administrative Expenses - The company incurred $30,000 in administrative fees for both the three months ended March 31, 2025, and 2024, under an agreement for office and administrative support[121]. - The company has incurred expenses related to being a public company and due diligence for prospective acquisition candidates[112]. Financing and Capital Structure - The company issued a Working Capital Note for $1,500,000 to Warrant Holdings Sponsor, which is repayable upon consummation of an initial business combination[122]. - The company placed approximately $345.0 million in a Trust Account, invested in U.S. government securities, until the completion of its initial business combination[108]. Compliance and Reporting - The Company complies with ASC 340-10-S99 and SEC Staff Accounting Bulletin Topic 5A regarding offering costs, which primarily consist of professional and registration fees related to the Public Offering[124]. - The Company qualifies as an "emerging growth company" under the JOBS Act, allowing it to delay the adoption of new or revised accounting standards[127]. - As an emerging growth company, the Company is exempt from certain reporting requirements, including auditor's attestation on internal controls and CEO compensation disclosures[128]. - The Company did not have any off-balance sheet arrangements as of the date of the Quarterly Report on Form 10-Q[126]. - The Company is classified as a smaller reporting company and is not required to provide certain market risk disclosures[130].

Exhibit 99.1 As used in this announcement, non-GAAP net income attributable to the Company's shareholders and non-GAAP basic and diluted net income per share and per ADS are defined to exclude share-based compensation expenses. See the unaudited reconciliation of GAAP and non-GAAP results at the end of this announcement. 1 · Net revenues were RMB28.8 billion (US$4.0 billion), an increase of 7.4% compared with the same quarter of 2024. · Games and related value-added services net revenues were RMB24.0 billio ...

FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______, 20___, to _____, 20___. Commission File Number 001-41272 HeartCore Enterprises, Inc. (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdict ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the transition period from to Commission file number 001-36548 ATARA BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) | Delaware | 46-0920988 | | --- | --- | | (State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.) | | 1280 Rancho Conejo Boulevard | | | Thousand Oaks, CA | 91320 | | (Address of Principal Executive Offices) | (Zip Code) | | Registrant's Teleph ...

Exhibit 99.1 Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress Atara has transferred all manufacturing responsibility to Pierre Fabre Laboratories, including all costs associated with the manufacturing and supply of tabelecleucel for development and commercialization worldwide Atara expects to reduce its operating expenses year-over-year by approximately 65% in 2025 as a result of implemented cost reduction initiatives • Atara has paused development of its CAR T progra ...